Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of delpacibart zotadirsen for Duchenne muscular dystrophy amenable to exon 44 skipping
NL-OMON61147Phase 3Not yet recruiting
- Sponsor
- Avidity Biosciences
- Start
- May 2026
- Modality
- Antibody Conjugates → Antibody-Based Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of delpacibart zotadirsen in Duchenne muscular dystrophy (DMD), sponsored by Avidity Biosciences. Planned start May 2026; status: not yet recruiting.
02
Drugs
delpacibart zotadirsen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON61147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61147.